



Company profile

Dermapharm is a fast-growing manufacturer of branded pharmaceuticals. Founded in 1991, the company is based in Grünwald near Munich. In addition to the main site in Brehna near Leipzig, Dermapharm operates further production, development and sales sites within Europe, primarily in Germany, Italy and Spain. Dermapharm currently employs around 2,563 people worldwide.


Reasons to invest

1. Clear focus on Germany as a quality location
2. High-growth pharmaceutical manufacturer in selected, profitable niche markets
3. In-house R&D competence
4. Pipeline with approx. 40 ongoing development projects
5. Successful track record in acquisitions
6. Expansion of international presence


Key figures (IFRS)

		2022	2021	2020	2019	2018
Revenue	EUR million	1.024,8	942,9	793,8	700,9	572,4
Adjusted EBITDA	EUR million	359,8	351,1	200,7	177,6	143,4
Adjusted EBITDA-margin	%	35,1	37,2	25,3	25,3	25,1
Unadjusted EBITDA	EUR million	331,3	354,4	184,5	168,5	139,6
Unadjusted EBITDA-margin	%	32,3	37,6	23,2	24,0	24,4
Operating income	EUR million	243,7	298,5	136,9	119,5	107,5
Earnings before taxes	EUR million	216,3	293,0	125,3	110,1	104,2
Profit or (loss) for the period	EUR million	132,6	208,9	85,9	77,8	75,2
Earnings per share	EUR	2,49	3,89	1,59	1,43	1,41


Revenue by segments (in EUR million)



Adjusted EBITDA by segment (in EUR million)



Adjusted EBITDA margin (in per cent)



2023 guidance

Group Revenue:


EUR 1.080 million to EUR 1.110 million

vs. previous year (EUR 1.024,8 million)

Adjusted Group EBITDA:

EUR 300 million to 310 million

vs. previous year (EUR 351,1 million)





Dermapharm reports in three segments

Branded pharmaceuticals and other healthcare products

With more than 380 active pharmaceutical ingredients, Dermapharm markets more than 1,200 drug approvals. The range of medicinal products, medical devices and food supplements is specialised in selected therapeutic areas in which Dermapharm occupies a leading market position, particularly in Germany.

Herbal extracts

In the "Herbal Extracts" segment, Dermapharm owns a globally leading manufacturer of plant extracts and herbal active ingredients for the pharmaceutical, nutraceutical, food, and cosmetics industry with its Spanish subsidiary Euromed S.A. and the market leader for dronabinol in Germany with the C³ Group. In January 2023, the segment was complemented by Arkopharma, the market leader for natural food supplements in France.

Parallel import business

Dermapharm's business model also includes a "parallel import business" segment, which is operated under the "axicorp" brand. Based on turnover, axicorp was one of the four parallel importers with the highest turnover in Germany in 2022.

Facts about Dermapharm share


Ticker symbol:	DMP
Ticker Symbol Bloomberg:	DMP:GR
Ticker Symbol Reuters:	DMPG.DE
WKN ISIN:	A2GS5D DE000A2GS5D8
Number of shares:	53.84 million
IPO:	9 February 2018

Shareholder structure


(Status: 28 March 2023)

Free float
32,3%

Themis Beteiligungs-
Aktiengesellschaft
67,7%



Dermapharm share in comparison



Financial calendar 2023 (half year 2023)

28 March 2023

Publication of Annual Report 2022

15 May 2023

Publication of Q1 Quarterly Report

14 June 2023

Annual General Meeting

Notice:

This publication contains various statements concerning the future development of the Dermapharm Group. These statements are based on both assumptions and estimates. Our assumptions involve risks and uncertainties that could cause actual results to differ materially from those anticipated. There are no plans to update the forward-looking statements. Throughout this publication, apparent differences may occur due to mathematical rounding during addition.